Major Pharma Short Interest Declines Ahead of Trump Comments

Health and Healthcare

Published: January 12, 2017 10:50 am

Last Updated: January 12, 2020 3:56 pm

The short interest data have been released for the December 30 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.

Drug prices have been under pressure due to the campaign rhetoric. But now that the election is over and Hillary Clinton — one of the main antagonists of these companies — is no longer running, the pressure has seemingly let up. However, recent comments from Trump have reignited discussion about the industry, suggesting that it may be “getting away with murder.” It’s worth noting that the short interest data were compiled before Trump made this comment.

Much more is to be seen from this industry going forward, much less these stocks. 24/7 Wall St has put together a bullish and bearish case for 2017 for the Dow’s health care sector.

Keep in mind that short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing the shares.

The December 30 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.

Short interest in Pfizer Inc. (NYSE: PFE) increased slightly to 44.49 million shares from the previous 44.19 million. Its shares were last seen at $32.45, within a 52-week trading range of $28.25 to $37.39.

The number of Merck & Co. Inc. (NYSE: MRK) shares short decreased to 17.31 million from 18.75 million in the previous period. Its shares were trading at $62.69, in a 52-week range of $47.97 to $65.46.

Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) short interest remained flat at 19.47 million shares, compared to the previous level. Shares were last trading at $34.30, in a 52-week range of $33.56 to $64.31.

The short interest drop in Bristol-Myers Squibb Co. (NYSE: BMY) was to 12.53 million shares, compared to the previous reading of 13.35 million. Shares were last trading at $56.48, within a 52-week range of $49.03 to $77.12.

The number of shares short in AbbVie Inc. (NYSE: ABBV) decreased to 33.40 million, compared to the previous 38.02 million. The stock was trading at $60.61, in a 52-week trading range of $50.71 to $68.12.

Eli Lilly and Co.’s (NYSE: LLY) short interest increased to 10.76 million shares from the previous 7.63 million. The stock was trading at $75.51. The 52-week range is $64.18 to $84.80.

Travel Cards Are Getting Too Good To Ignore (sponsored)

Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.

We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.

It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.

We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.